Ray Amrit 4

What Happened

• Ray Amrit, a director of Ultragenyx Pharmaceutical Inc. (RARE), was granted equity awards on 2026-05-14: 7,751 restricted stock units (RSUs) and a separate derivative award covering 14,058 shares. Both awards were reported as acquisitions at $0.00 per share (typical for grant awards) and therefore have no immediate cash value to the insider.
• These awards are grants (transaction code A) rather than open-market purchases or sales — they are compensation equity, not a buy or sell that signals personal liquidity or immediate market sentiment.

Key Details

• Transaction date: May 14, 2026; Form 4 filed May 18, 2026 (timely filing).
• Awards: 7,751 RSUs (F1) and 14,058- share derivative award/option (F2), both recorded at $0.00 per share.
• Vesting: Both awards vest in full on the earlier of (i) the Company’s next Annual Meeting of Stockholders or (ii) May 14, 2027 (see footnotes F1 and F2).
• Shares owned after transaction: Not specified in the provided filing details.
• Transaction code: A = Award/Grant. No 10b5-1, tax-withholding, cashless exercise, or late-filing notes in this report.

Context

• These grants are standard director compensation and will only convert to owned shares if/when vesting conditions are met; they do not represent an immediate purchase or sale. For retail investors, awards like RSUs are common retention/compensation tools and are generally neutral until vested and sold.